Tags

Type your tag names separated by a space and hit enter

[Leishmaniasis--oral treatment with hexadecylphosphocholine].
Wien Klin Wochenschr. 2004; 116 Suppl 4:24-9.WK

Abstract

Hexadecylphosphocholine (HDPC, Miltefosine, Impavido) was synthesized at the Max-Planck-Institut für Biophysikalische Chemie in Göttingen, Germany and successfully used for the therapy of cancer metastases. At the Institute of General and Tropical Hygiene of Göttingen University the antiparasitic efficacy--earlier mentioned by Croft et al. (1987)--could be established for the first time in animals after oral administration. In India Impavido has been recently registered for the treatment of visceral leishmaniasis as the first oral medication in this indication. Clinical studies in India--actually a phase IV study is running--and Columbia (cutaneous leishmaniosis) demonstrated the excellent efficacy of this oral treatment also in patients with Antimon resistance. The cure rates are above 90% with low side effects (Impavido twice 50 mg capsules daily over 28 days).

Authors+Show Affiliations

Institut für Allgemeine Hygiene der Universität Göttingen/Tropenmedizinisches Beratungszentrum, Göttingen, Deutschland. info@labor-wagnerstibbe.deNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
English Abstract
Journal Article

Language

ger

PubMed ID

15683039

Citation

Bommer, Wolfgang, et al. "[Leishmaniasis--oral Treatment With Hexadecylphosphocholine]." Wiener Klinische Wochenschrift, vol. 116 Suppl 4, 2004, pp. 24-9.
Bommer W, Eibl HJ, Engel KR, et al. [Leishmaniasis--oral treatment with hexadecylphosphocholine]. Wien Klin Wochenschr. 2004;116 Suppl 4:24-9.
Bommer, W., Eibl, H. J., Engel, K. R., Kuhlencord, A., Sindermann, H., Sundar, S., & Zappel, H. (2004). [Leishmaniasis--oral treatment with hexadecylphosphocholine]. Wiener Klinische Wochenschrift, 116 Suppl 4, 24-9.
Bommer W, et al. [Leishmaniasis--oral Treatment With Hexadecylphosphocholine]. Wien Klin Wochenschr. 2004;116 Suppl 4:24-9. PubMed PMID: 15683039.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Leishmaniasis--oral treatment with hexadecylphosphocholine]. AU - Bommer,Wolfgang, AU - Eibl,Hans J, AU - Engel,Kirsten R, AU - Kuhlencord,Armin, AU - Sindermann,Herbert, AU - Sundar,Sham, AU - Zappel,Hildegard, PY - 2005/2/3/pubmed PY - 2005/3/12/medline PY - 2005/2/3/entrez SP - 24 EP - 9 JF - Wiener klinische Wochenschrift JO - Wien Klin Wochenschr VL - 116 Suppl 4 N2 - Hexadecylphosphocholine (HDPC, Miltefosine, Impavido) was synthesized at the Max-Planck-Institut für Biophysikalische Chemie in Göttingen, Germany and successfully used for the therapy of cancer metastases. At the Institute of General and Tropical Hygiene of Göttingen University the antiparasitic efficacy--earlier mentioned by Croft et al. (1987)--could be established for the first time in animals after oral administration. In India Impavido has been recently registered for the treatment of visceral leishmaniasis as the first oral medication in this indication. Clinical studies in India--actually a phase IV study is running--and Columbia (cutaneous leishmaniosis) demonstrated the excellent efficacy of this oral treatment also in patients with Antimon resistance. The cure rates are above 90% with low side effects (Impavido twice 50 mg capsules daily over 28 days). SN - 0043-5325 UR - https://www.unboundmedicine.com/medline/citation/15683039/[Leishmaniasis__oral_treatment_with_hexadecylphosphocholine]_ L2 - http://www.diseaseinfosearch.org/result/4166 DB - PRIME DP - Unbound Medicine ER -